CROSS-COMPOUND MATRIX
Compare the Signal, Then the Outcome
Mechanism, evidence maturity, and endpoint strength across MOTS-c, CJC-1295, tesamorelin, and ipamorelin.
The short version
These four peptides do not answer the same research question. MOTS-c is a mitochondrial stress and metabolism signal, not a direct GHRH or ghrelin-receptor agonist [1][3][6]. CJC-1295 is a long-acting GHRH analog with small human studies showing sustained GH and IGF-1 changes [11][12]. Tesamorelin is another GHRH analog, but its program measured visceral and liver fat in randomized trials of adults with HIV-associated lipodystrophy [13][15][17]. Ipamorelin activates the ghrelin receptor, creates an acute GH pulse, and has a controlled human outcome trial that missed its primary endpoint [20][21].
The practical comparison is therefore not “which is strongest.” It is which link in the evidence chain has been tested. Target engagement, hormone response, tissue change, and patient-important benefit are separate levels. CJC-1295 is strongest on sustained axis biomarkers. Tesamorelin is strongest on body-composition outcomes in a narrow population. MOTS-c is richest in preclinical mitochondrial biology. Ipamorelin establishes acute pharmacology while leaving long-term efficacy and safety unresolved.
The endpoint matrix
| Compound | Primary research target | Best-supported evidence layer | What the layer cannot stand in for |
|---|---|---|---|
| MOTS-c | Mitochondrial stress signaling; CK2 and AMPK-linked pathways | Cell and animal mechanisms; observational human biomarker association [1][2][5][6] | Human efficacy from external administration |
| CJC-1295 | GHRH receptor and downstream GH/IGF-1 axis | Sustained GH and IGF-1 pharmacodynamics in small human studies [10][11][12] | Fat loss, recovery, function, or long-term safety |
| Tesamorelin | GHRH receptor, GH/IGF-1, visceral-fat lipolysis | Randomized body-composition outcomes in HIV-associated lipodystrophy [13][15][17] | General-purpose fat loss or unmeasured clinical-event benefit |
| Ipamorelin | GHS-R1a ghrelin receptor and acute GH release | Acute human PK/PD; negative primary result in a short outcome trial [20][21] | Proven recovery, body composition, or chronic safety |
Mechanism is the first column, not the verdict
CJC-1295 and tesamorelin share an upstream receptor class. Both are GHRH analogs that stimulate the pituitary and increase endogenous GH, with downstream IGF-1 response [8]. Their evidence files diverge after that common mechanism. CJC-1295 studies in this corpus concentrate on duration, pulsatility, and serum biomarkers [10][11][12]. Tesamorelin studies move into measured visceral and hepatic fat outcomes [13][15][17].
Ipamorelin reaches the GH signal through GHS-R1a rather than GHRH-R. Acute modeling captures a short half-life and a discrete GH pulse [21]. The mechanism does not rescue a failed primary outcome in the perioperative trial [20]. MOTS-c is further removed: direct CK2 binding, AMPK-linked metabolism, and stress-related nuclear signaling are its central mechanisms [1][5][6]. Describing all four simply as GH peptides would erase that difference.
Evidence maturity changes the allowable sentence
For MOTS-c, the defensible sentence is that experiments in cells and animals report specific metabolic and muscle effects, while a human cohort found an association between endogenous circulating peptide and risk [1][2][4][7]. “Improves human metabolism” would go beyond the design.
For CJC-1295, the defensible sentence is that small human studies produced sustained increases in GH and IGF-1 with preserved pulsatility [11][12]. “Reduces body fat” would replace an unmeasured outcome with a surrogate.
For tesamorelin, it is accurate to report randomized reductions in visceral and hepatic fat in adults with HIV-associated abdominal fat accumulation [13][15]. It is not accurate to generalize those effects to every population. Continued treatment also mattered because visceral fat returned after discontinuation [17].
For ipamorelin, it is accurate to report acute GH pharmacology and a nonsignificant primary result in postoperative ileus [20][21]. A recent ferret result and an older rat bone-growth experiment remain animal findings [18][22].
How to read biomarkers without overreach
A useful biomarker has a defined job. GH concentration can show a secretory response, but sampling is sensitive to pulsatility. IGF-1 integrates more of the downstream signal, but it remains a growth-factor concentration rather than a direct measure of fat distribution, strength, recovery, or events. Body-composition imaging measures a tissue compartment, yet even that is not the same as demonstrating longer life or fewer cardiovascular events.
The strongest claim should match the highest directly measured rung. CJC-1295 reaches hormone response [11][12]. Tesamorelin reaches randomized tissue outcomes in a specified population [13][15][17]. Ipamorelin reaches acute response and one unsuccessful clinical hypothesis test [20][21]. MOTS-c reaches mechanisms, animal phenotypes, and human association [1][2][4][6][7]. This hierarchy is not a score of molecular interest. It is a boundary around inference.
Safety evidence is also endpoint evidence
Short studies can report short-term tolerability; they cannot establish chronic safety. That limit is most visible for CJC-1295 and ipamorelin, where the human datasets are small or brief [10][11][12][20][21]. A chronic rat toxicology signal from a different ghrelin-receptor agonist raises a class-level cardiovascular question for ipamorelin, but it is not an ipamorelin injury finding [19].
Tesamorelin has the broadest controlled safety context in this set and an NIH liver-safety assessment, but its evidence still belongs to its studied indication and observation periods [13][14][17]. MOTS-c lacks human intervention safety trials. Across all four, absence of a detected event is interpretable only against sample size, duration, population, and the event the study was equipped to detect.